Publication of results showing that the PCI technology can significantly improve vaccination treatment in a melanoma model NewsKristin EivindvikDecember 9, 2014
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million NewsKristin EivindvikDecember 9, 2014
PCI Biotech presenting at DNB Markets Health Care Conference 2014 NewsKristin EivindvikNovember 13, 2014
PCI Biotech presented at the World Vaccine Congress Europe 2014 NewsKristin EivindvikOctober 14, 2014
PCI Biotech to present at SACHS Associates 14th Annual Biotech in Europe Forum NewsKristin EivindvikSeptember 30, 2014
Successful completion of the second group in the intra-tumour light dose escalation part of the ENHANCE study NewsKristin EivindvikAugust 22, 2014
PCI Biotech to present at The 2014 BIO International Convention, San Diego NewsKristin EivindvikJune 20, 2014
Successful completion of the first dose cohort in the study for patients with inoperable bile duct cancer NewsKristin EivindvikMay 7, 2014
First patient treated in the study of Amphinex in patients with bile duct cancer (Cholangiocarcinoma) NewsadminFebruary 4, 2014
PCI Biotech awarded NOK 12.5 million from The Research Council of Norway to further development of PCI for use in vaccination NewsadminJanuary 30, 2014
Successful completion of the first group in the intra-tumour light dose escalation part of the ENHANCE study NewsadminJanuary 24, 2014
Results from preclinical in vivo vaccination studies showing that the PCI technology can significantly improve therapeutically relevant immune responses accepted for publication NewsadminDecember 12, 2013
Update on clinical studies – both clinical studies now open for patient inclusion. NewsadminDecember 12, 2013
